Free Trial
NASDAQ:NERV

Minerva Neurosciences (NERV) Stock Price, News & Analysis

Minerva Neurosciences logo
$6.18 -0.07 (-1.12%)
As of 03:01 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Minerva Neurosciences Stock (NASDAQ:NERV)

Advanced

Key Stats

Today's Range
$6.02
$6.33
50-Day Range
$5.18
$8.07
52-Week Range
$1.30
$12.46
Volume
48,776 shs
Average Volume
204,583 shs
Market Capitalization
$270.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50
Consensus Rating
Hold

Company Overview

Minerva Neurosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

NERV MarketRank™: 

Minerva Neurosciences scored higher than 43% of companies evaluated by MarketBeat, and ranked 476th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Minerva Neurosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Minerva Neurosciences has a consensus price target of $10.50, representing about 70.3% upside from its current price of $6.17.

  • Amount of Analyst Coverage

    Minerva Neurosciences has only been the subject of 3 research reports in the past 90 days.

  • Read more about Minerva Neurosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Minerva Neurosciences are expected to grow in the coming year, from ($0.60) to ($0.48) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Minerva Neurosciences is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Minerva Neurosciences is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Minerva Neurosciences' valuation and earnings.
  • Percentage of Shares Shorted

    2.94% of the float of Minerva Neurosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Minerva Neurosciences has a short interest ratio ("days to cover") of 5.07.
  • Change versus previous month

    Short interest in Minerva Neurosciences has recently increased by 13.26%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Minerva Neurosciences does not currently pay a dividend.

  • Dividend Growth

    Minerva Neurosciences does not have a long track record of dividend growth.

  • News Sentiment

    Minerva Neurosciences has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Minerva Neurosciences this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Minerva Neurosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.40% of the stock of Minerva Neurosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    34.56% of the stock of Minerva Neurosciences is held by institutions.

  • Read more about Minerva Neurosciences' insider trading history.
Receive NERV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NERV Stock News Headlines

If You Have $50k+ on Coinbase, This Will Ruin Your Day
October 14th, 2025, CNBC quietly published an interview with BlackRock's CEO, who went on live television and said: "THIS is the next wave of opportunity for the next 10 years." Right now, the entire financial system is being recoded. $10 trillion in assets is moving to new digital rails. BlackRock. JP Morgan. Visa... They're all positioning. Position yourself before institutions lock you out.tc pixel
Minerva Announces Leadership Transition
See More Headlines

NERV Stock Analysis - Frequently Asked Questions

Minerva Neurosciences' stock was trading at $4.02 at the beginning of the year. Since then, NERV stock has increased by 53.4% and is now trading at $6.1660.

Minerva Neurosciences, Inc (NASDAQ:NERV) posted its quarterly earnings results on Tuesday, May, 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by $0.04.

Minerva Neurosciences shares reverse split before market open on Tuesday, June 21st 2022.The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Minerva Neurosciences (NERV) raised $33 million in an initial public offering (IPO) on Thursday, June 26th 2014. The company issued 5,454,545 shares at $6.00 per share.

Top institutional investors of Minerva Neurosciences include Cannon Global Investment Management LLC (0.04%).
View institutional ownership trends
.

Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Minerva Neurosciences investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Meta Platforms (META), NIO (NIO), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO) and VBI Vaccines (VBIV).

Company Calendar

Today
5/06/2026
Last Earnings
5/12/2026
Next Earnings (Estimated)
5/12/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NERV
CIK
1598646
Fax
N/A
Employees
9
Year Founded
2007

Price Target and Rating

High Price Target
$14.00
Low Price Target
$7.00
Potential Upside/Downside
+69.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($26.80)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$293.42 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-35.62%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
36.29
Quick Ratio
36.29

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($3.25) per share
Price / Book
-1.90

Miscellaneous

Outstanding Shares
43,840,000
Free Float
39,282,000
Market Cap
$270.93 million
Optionable
Not Optionable
Beta
-0.08

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:NERV) was last updated on 5/6/2026 by MarketBeat.com Staff.
From Our Partners